Trial Profile
A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Acarbose
- Indications Hypoglycaemia
- Focus Pharmacokinetics; Therapeutic Use
- 10 Jul 2019 Status changed from recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 30 Nov 2018 to 30 Nov 2019.
- 14 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Nov 2019.